136 related articles for article (PubMed ID: 37095064)
1. Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): Results of an open-label randomized controlled trial.
Muthu V; Gogineni RR; Agarwal R; Prasad KT; Sehgal IS; Dhooria S; Aggarwal AN; Rudramurthy SM; Singh H; Garg M; Chakrabarti A
Mycoses; 2023 Aug; 66(8):688-696. PubMed ID: 37095064
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
3. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
[TBL] [Abstract][Full Text] [Related]
4. Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis.
Muthu V; Dhooria S; Sehgal IS; Prasad KT; Rudramurthy SM; Aggarwal AN; Chakrabarti A; Agarwal R
Pulm Pharmacol Ther; 2023 Aug; 81():102226. PubMed ID: 37230237
[TBL] [Abstract][Full Text] [Related]
5. [Pulmonary mucormycosis: benefit of aerosol amphotericin B?].
Furco A; Mouchet B; Carbonnelle M; Vallerand H
Rev Mal Respir; 2001 Jun; 18(3):309-13. PubMed ID: 11468594
[TBL] [Abstract][Full Text] [Related]
6. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options.
Riley TT; Muzny CA; Swiatlo E; Legendre DP
Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416
[TBL] [Abstract][Full Text] [Related]
7. A pilot randomized trial of nebulized amphotericin in patients with allergic bronchopulmonary aspergillosis.
Ram B; Aggarwal AN; Dhooria S; Sehgal IS; Garg M; Behera D; Chakrabarti A; Agarwal R
J Asthma; 2016 Jun; 53(5):517-24. PubMed ID: 26666774
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
9. Safety and usefulness of nebulized liposomal amphotericin B: Systematic scoping review.
Hagiya H; Nishimura Y; Otsuka F
Pulm Pharmacol Ther; 2023 Oct; 82():102233. PubMed ID: 37414132
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive use of saturated solution of potassium iodide (SSKI) with liposomal amphotericin B (L-AMB) in mucormycosis achieves favorable response, shortened dose and duration of amphotericin: A retrospective study from a COVID-19 tertiary care center.
Mrig S; Sardana K; Arora P; Narula V; Arora S; Kapoor A; Baruah RR; Sen P; Agarwal S; Sachdeva S; Dewan A; Panesar S
Am J Otolaryngol; 2022; 43(3):103465. PubMed ID: 35429848
[TBL] [Abstract][Full Text] [Related]
11. Treatment of invasive fungal sinusitis with liposomal amphotericin B: a report of four cases.
Sungkanuparph S; Sathapatayavongs B; Kunachak S; Luxameechanporn T; Cheewaruangroj W
J Med Assoc Thai; 2001 Apr; 84(4):593-601. PubMed ID: 11460976
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B formulations: a comparative review of efficacy and toxicity.
Hamill RJ
Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
[TBL] [Abstract][Full Text] [Related]
13. Rhinocerebral mucormycosis treated with amphotericin B colloidal dispersion in three patients.
Moses AE; Rahav G; Barenholz Y; Elidan J; Azaz B; Gillis S; Brickman M; Polacheck I; Shapiro M
Clin Infect Dis; 1998 Jun; 26(6):1430-3. PubMed ID: 9636875
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.
Arrieta AC; Shea K; Dhar V; Cleary JP; Kukreja S; Morris M; Vargas-Shiraishi OM; Ashouri N; Singh J
Clin Ther; 2010 Feb; 32(2):265-71. PubMed ID: 20206784
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
16. Antifungal prophylaxis with nebulized amphotericin-B in solid-organ transplant recipients with severe COVID-19: a retrospective observational study.
Rombauts A; Bodro M; Daniel Gumucio V; Carbonell I; Favà À; Lladó L; González-Costello J; Oppenheimer F; Castel-Lavilla MÁ; Len O; Marquez-Algaba E; Nuvials-Casals X; Martínez González D; Lacasa JS; Carratalà J; Sabé N
Front Cell Infect Microbiol; 2023; 13():1165236. PubMed ID: 37180450
[TBL] [Abstract][Full Text] [Related]
17. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.
Spellberg B; Ibrahim AS; Chin-Hong PV; Kontoyiannis DP; Morris MI; Perfect JR; Fredricks D; Brass EP
J Antimicrob Chemother; 2012 Mar; 67(3):715-22. PubMed ID: 21937481
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of rhinocerebral mucormycosis by a combination of aggressive surgical debridement and the use of systemic liposomal amphotericin B and local therapy with nebulized amphotericin--a case report.
Raj P; Vella EJ; Bickerton RC
J Laryngol Otol; 1998 Apr; 112(4):367-70. PubMed ID: 9659500
[TBL] [Abstract][Full Text] [Related]
19. Treating progressive disseminated histoplasmosis in people living with HIV.
Murray M; Hine P
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD013594. PubMed ID: 32343003
[TBL] [Abstract][Full Text] [Related]
20. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
